Search results
Is it COVID, the flu, or RSV? A Roche test could soon provide the answer in 20 minutes
IndyStar | The Indianapolis Star via Yahoo News· 3 days agoThis past winter, hospitals and clinics across Indiana filled up with patients suffering from...
FDA gives nod to RSV vaccine for people in their 50s
Medical Xpress· 6 days agoDrugmaker GSK's Arexvy vaccine, as well as vaccines from Pfizer and Moderna, are already approved for use in adults 60 and older, since age brings higher...
Pete Buttigieg on fatherhood
CBS News via Yahoo News· 2 hours agoHe's been a Rhodes scholar, Navy veteran, mayor, presidential candidate, and now Secretary of Transportation, but Pete Buttigieg has another title: Papa....
Is it COVID, the flu, or RSV? A Roche test could soon provide the answer in 20 minutes
The Indianapolis Star· 3 days agoThis past winter, hospitals and clinics across Indiana filled up with patients suffering from...
FDA Gives Nod to RSV Vaccine for People in Their 50s
US News & World Report· 6 days agoThe U.S. Food and Drug Administration on Friday has for the first time approved the use of a respiratory syncytial virus (RSV) vaccine for people in their 50s who are at increased ...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 4 days agoThe vaccine, dubbed mResvia, was developed to protect people age 60 and older from RSV. Usually, RSV...
Pete Buttigieg on fatherhood
CBS News· 2 hours agoWhen it comes to handling a pair of toddlers, Pete Buttigieg, the unflappable Secretary of Transportation, may appear a little jet-lagged. Pete and his...
Why Moderna Stock Is a No-Brainer Buy Right Now
Motley Fool via Yahoo Finance· 6 days agoThat's changing. On May 31, Moderna won U.S. Food and Drug Administration (FDA) approval for its respiratory syncytial virus (RSV) vaccine mResvia. This...
Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral...
The News & Observer· 5 days agoA First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More
Why Moderna Stock Is a No-Brainer Buy Right Now | The Motley Fool
The Motley Fool· 6 days agoIn 2022, the biotech company generated sales of nearly $18.9 billion, but it expects revenue of only...
